DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for leptospirosis — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLeptospirosis maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for leptospirosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
arginine vasopressin receptor 2 (AVPR2) — AVPR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7DW9 · 2.6 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
In a 1984 randomised, double-blinded trial, 29 hospitalised patients with leptospirosis received either doxycycline 100 mg orally twice a day or placebo for seven days. Duration of illness before therapy and severity were the same in both groups. Doxycycline reduced the duration of illness by two days and favourably affected fever, malaise, headache, and myalgias. Treatment prevented leptospiruria and had no adverse effects. The authors concluded doxycycline is effective therapy for patients with leptospirosis.
A 2000 systematic review of randomised controlled trials on interventions for leptospirosis searched EMBASE, LILACS, MEDLINE, the Cochrane Controlled Clinical Trials Database, and the Cochrane Hepato-Biliary Group Randomized Trials register without language or date restrictions. The search located 163 studies. Only two hits were selected, both protocols of Cochrane systematic reviews — one evaluating antibiotics for treatment, the other evaluating antibiotics for prevention. No complete systematic reviews on interventions for leptospirosis were found. The authors stated that any intervention for prevention or treatment remains unclear for guidelines and practice.
A 1945 journal article on the pathogenesis of leptospirosis was published in The Journal of Infectious Diseases. It contains no clinical trial data on treatment outcomes.
The evidence base for treating leptospirosis rests on a single small trial from 1984. No systematic review has been completed. What is missing is a modern, adequately powered randomised trial, funding for such a trial, and patient stratification by disease severity and time to treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine · 1984 · 234 citations
Doxycycline Therapy for Leptospirosis
AbstractTo study antibiotic efficacy, 29 patients with leptospirosis were treated in a randomized, double-blinded fashion with doxycycline, 100 mg orally twice a day, or placebo. Therapy was given for 7 days in a hospital, and patients were followed for 3 weeks afterwards. Duration of illness before therapy and severity of illness were the same in both groups. Doxycycline reduced the duration of illness by 2 days and favorably affected fever, malaise, headache, and myalgias. Treatment prevented leptospiruria and had no adverse effects. Doxycycline is effective in therapy for patients with leptospirosis.
The Journal of Infectious Diseases · 1945 · 36 citations
Studies on the Pathogenesis of Leptospirosis
AbstractJournal Article Studies on the Pathogenesis of Leptospirosis Get access Abram B. Stavitsky Abram B. Stavitsky From the Department of Bacteriology and Immunology, Medical School, University of Minnesota, Minneapolis Search for other works by this author on: Oxford Academic PubMed Google Scholar The Journal of Infectious Diseases, Volume 76, Issue 3, May 1945, Pages 179–192, https://doi.org/10.1093/infdis/76.3.179 Published: 01 May 1945 Article history Received: 12 January 1945 Published: 01 May 1945
Revista do Instituto de Medicina Tropical de São Paulo · 2000 · 20 citations · open access
Systematic reviews on leptospirosis
AbstractOBJECTIVES: To find the existing clinical evidence on interventions for leptospirosis. The objective is to evaluate the effectiveness and safety of any intervention on leptospirosis through systematic reviews of randomized controlled trials (RCTs). DATA SOURCE: The sources of studies used (where there were no limitations concerning language, date, or other restrictions) were: EMBASE, LILACS, MEDLINE, the Cochrane Controlled Clinical Trials Database, and the Cochrane Hepato-Biliary Group Randomized Trials register. TYPE OF STUDY: All systematic reviews of randomized controlled trials. PARTICIPANTS: patients with clinical and/or laboratorial diagnosis of leptospirosis, and subjects potencially exposed to leptospirosis as defined by the authors INTERVENTIONS: any intervention for leptospirosis (as antibiotics or vaccines for prevention or treatment). DATA COLLECTION: The assessment will be independently made by the reviewers and cross-checked. The external validity was assessed by analysis of: studies, interventions, and outcomes. DATA SYNTHESIS: Located 163 studies using the search strategy described above, at the electronic databases above. Only 2 hits were selected, which are protocols of systematic reviews of Cochrane Collaboration, and not full reviews. One of the protocols evaluates antibiotics for treatment, and the other evaluates antibiotics for prevention of leptospirosis. CONCLUSIONS: There were not complete systematic reviews on interventions for leptospirosis. Any interventions for leptospirosis, such as prevention and treatment remains unclear for guidelines and practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
